MAZZARELLA, LUCA
MAZZARELLA, LUCA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data
2017 G.E.M. Melloni, L. Mazzarella, L. Bernard, M. Bodini, A. Russo, L. Luzi, P.G. Pelicci, L. Riva
A new approach to assess drug sensitivity in cells for novel drug discovery
2018 L. Mazzarella, G. Curigliano
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis
2021 A. Esposito, A. Marra, V. Bagnardi, S. Frassoni, S. Morganti, G. Viale, P. Zagami, G.M. Varano, G. Buccimazza, F. Orsi, K. Venetis, L. Mazzarella, G. Viale, N. Fusco, C. Criscitiello, G. Curigliano
Cetuximab for treating non-small cell lung cancer
2018 L. Mazzarella, A. Guida, G. Curigliano
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer
2018 B. Duso, D. Trapani, G. Viale, C. Criscitiello, P. D'Amico, C. Belli, L. Mazzarella, M. Locatelli, I. Minchella, G. Curigliano
Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis
2019 M. Elgendy, M. Ciro, A. Hosseini, J. Weiszmann, L. Mazzarella, E. Ferrari, R. Cazzoli, G. Curigliano, A. DeCensi, B. Bonanni, A. Budillon, P.G. Pelicci, V. Janssens, M. Ogris, M. Baccarini, L. Lanfrancone, W. Weckwerth, M. Foiani, S. Minucci
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
2021 E. de Guillebon, M. Jimenez, L. Mazzarella, F. Betsou, P. Stadler, I. Peták, E. Jeannot, L. Chanas, N. Servant, G. Marret, B.A. Duso, F. Legrand, K.N. Kornerup, S.H. Bernhart, G. Balogh, R. Dóczi, P. Filotás, G. Curigliano, I. Bièche, J. Guérin, A. Dirner, C. Neuzillet, N. Girard, E. Borcoman, L. Larbi Chérif, P. Tresca, D.B. Roufai, C. Dupain, S. Scholl, F. André, X. Fernandez, T. Filleron, M. Kamal, C. Le Tourneau
Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: Back to the future?
2012 J.T. Ribeiro, L.T. Macedo, G. Curigliano, L. Fumagalli, M. Locatelli, M. Dalton, A. Quintela, J.B.C. Carvalheira, S. Manunta, L. Mazzarella, J. Brollo, A. Goldhirsch
Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in PtII complexes on human carcinoma cell lines: A comparative study with cisplatin
2013 N. Ferri, S. Cazzaniga, L. Mazzarella, G. Curigliano, G. Lucchini, D. Zerla, R. Gandolfi, G. Facchetti, M. Pellizzoni, I. Rimoldi
Detection of clustered circulating tumour cells in early breast cancer
2021 I. Krol, F.D. Schwab, R. Carbone, M. Ritter, S. Picocci, M.L. De Marni, G. Stepien, G.M. Franchi, A. Zanardi, M.D. Rissoglio, A. Covelli, G. Guidi, D. Scarinci, F. Castro-Giner, L. Mazzarella, C. Doglioni, F. Borghi, P. Milani, C. Kurzeder, W.P. Weber, N. Aceto
DOTS-Finder : a comprehensive tool for assessing driver genes in cancer genomes
2014 G.E.M. Melloni, A.G.E. Ogier, S. de Pretis, L. Mazzarella, M. Pelizzola, P.G. Pelicci, L. Riva
Entinostat for the treatment of breast cancer
2017 D. Trapani, A. Esposito, C. Criscitiello, L. Mazzarella, M. Locatelli, I. Minchella, S. Minucci, G. Curigliano
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity
2020 L. Mazzarella, S. Giugliano, P. D'Amico, C. Belli, B.A. Duso, M. Rescigno, G. Curigliano
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols
2012 M. Breccia, L. Mazzarella, V. Bagnardi, D. Disalvatore, G. Loglisci, G. Cimino, A.M. Testi, G. Avvisati, M.C. Petti, C. Minotti, R. Latagliata, R. Foà, P.G. Pelicci, F. Lo Coco
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach
2018 C. Belli, M. Zuin, L. Mazzarella, D. Trapani, P. D'Amico, E. Guerini-Rocco, B. Achutti Duso, G. Curigliano
Machine learning-based reclassification of germline variants of unknown significance: The RENOVO algorithm
2021 V. Favalli, G. Tini, E. Bonetti, G. Vozza, A. Guida, S. Gandini, P.G. Pelicci, L. Mazzarella
Master protocols in immuno-oncology : Do novel drugs deserve novel designs?
2020 L. Mazzarella, S. Morganti, A. Marra, D. Trapani, G. Tini, P. Pelicci, G. Curigliano
Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients
2013 L. Mazzarella, D. Disalvatore, V. Bagnardi, N. Rotmensz, D. Galbiati, S. Caputo, G. Curigliano, P.G. Pelicci
p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value
2019 A. Santoro, T. Vlachou, L. Luzi, G. Melloni, L. Mazzarella, E. D'Elia, X. Aobuli, C.E. Pasi, L. Reavie, P. Bonetti, S. Punzi, L. Casoli, A. Sabo, M.C. Moroni, G.I. Dellino, B. Amati, F. Nicassio, L. Lanfrancone, P.G. Pelicci
Pharmacological management of male breast cancer
2020 B.A. Duso, D. Trapani, A. Marra, P. D'Amico, E. Guerini Rocco, N. Fusco, L. Mazzarella, C. Criscitiello, A. Esposito, G. Curigliano